Cerebrovascular disease vascular disease in the brain
Conditions
Interventions
Patients will receive, randomly and sequentially, dobutamine (2-15 µg/kg/min)
to increase the cardiac output and phenylephrine (0.15-1 µg/kg/min) to increase
the blood pressure.
Sponsors
Anesthesiologie
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adults, aged 18 years or above Indication for extracranial-intracranial bypass surgery
Exclusion criteria
Exclusion criteria: Patients within two weeks after a subarachnoid hemorrhage Language barrier Pregnancy Hypertrophic cardiomyoapthy Left ventricular outflow tract obstruction Severe, untreated, ventricular arrhythmia Severe hyperthyroidism Recent myocardial infarction ( 180 mmHg under general anesthesia before start of the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean change in graft flow rate (ml/min) during dobutamine administration to increase the cardiac output with 10% and the mean change in flow rate during administration of phenylephrine to increase the blood pressure with 10%. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the difference in change in graft flow rate, cardiac output and blood pressure (compared to the reference stage) between the intervention to increase the cardiac output and the intervention to increase the blood pressure. | — |
Countries
Netherlands
Outcome results
None listed